Exicure (NASDAQ:XCUR) Stock Price Down 8.7%

Shares of Exicure, Inc. (NASDAQ:XCUR) dropped 8.7% on Wednesday . The stock traded as low as $0.58 and last traded at $0.58. Approximately 30,265 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 412,076 shares. The stock had previously closed at $0.64.

Exicure Trading Down 8.7 %

The firm has a 50 day simple moving average of $0.62 and a two-hundred day simple moving average of $0.61. The company has a market capitalization of $5.02 million, a PE ratio of 0.35 and a beta of 1.31.

Insider Activity at Exicure

In related news, major shareholder Co. Ltd. Dgp sold 3,400,000 shares of Exicure stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.32, for a total value of $4,488,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 8.40% of the company’s stock.

Institutional Trading of Exicure

A number of institutional investors have recently modified their holdings of XCUR. Citadel Advisors LLC acquired a new position in Exicure during the second quarter worth $66,000. Goldman Sachs Group Inc. raised its holdings in Exicure by 329.2% during the first quarter. Goldman Sachs Group Inc. now owns 147,703 shares of the company’s stock worth $29,000 after purchasing an additional 113,293 shares during the last quarter. Finally, UBS Group AG raised its holdings in Exicure by 1,766.7% during the first quarter. UBS Group AG now owns 186,674 shares of the company’s stock worth $37,000 after purchasing an additional 176,674 shares during the last quarter. 42.82% of the stock is currently owned by hedge funds and other institutional investors.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.